Agilent’s contract Lead Discovery Service utilizes label-free RapidFire technology for direct quantitation of a wide range of native analytes across diverse therapeutic areas. In our labs, RapidFire mass spectrometry has been used to screen tens of millions of compounds, helping organizations to discover promising new drugs. RapidFire data is delivered in a format that is easy to interpret and analyze within existing laboratory workflows. This, combined with short turn-around times, enables quick decisions on potential lead compounds.
The ideal candidate assays for RapidFire Lead Discovery are often the same ones that are difficult to screen using traditional HTS techniques. These include enzymatic targets that have lipidic or very small substrates, epigenetic targets and others.